Status: Not yet recruiting
A Phase II Trial of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody
A Phase II, Single-Center, Randomized, Blinded, Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Recombinant Human Anti-Rabies Virus Monoclonal Antibody Injection in Healthy Subjects
Participants needed: 200
Trial details
Phase: Phase 2Age: 18-60Biological sex: AllType: InterventionalSponsor: Lanzhou Institute of Biological Products Co., LtdUpdated: Mar 3, 2026Locations: 1
Eligibility criteria
Healthy individuals aged 18-60 years (inclusive), regardless of gender, capable... [+4]
Known allergy to the investigational product (including excipients or similar dr... [+20]